{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:57:48Z","timestamp":1776160668507,"version":"3.50.1"},"reference-count":27,"publisher":"Mark Allen Group","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Nurs"],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:p>Intravenous (IV) therapy is a cornerstone of modern medical care, enabling rapid and controlled delivery of fluids, medications and nutrition. However, consideration must be given to the use of in-line filters to maintain patient safety. This product focus outlines the benefits of using Pall Medical in-line filters, which have emerged as a vital measure to mitigate the risks of inadvertently administering particulate matter, microorganisms, endotoxins, and air bubbles during infusion therapy. The use of Pall Medical in-line filters can enhance patient safety and clinical outcomes, particularly in high-risk settings such as neonatal care, oncology, and intensive care units. The use of these filters is outlined in two clinical case studies here. First, the use of Pall Medical TNA1E and NLF2E 1.2 \u00b5m (lipid) filters, which has been shown to adhere to current practice guidelines. The case study discusses the use of 1.2 \u00b5m in-line filters for the administration of parenteral nutrition in paediatric care to reduce complications and ensure safe infusion practice. The second case study details the integration of the Pall Medical 0.2 \u00b5m Supor AEF low protein binding IV in-line filter for the administration of monoclonal antibodies in an outpatient infusion centre setting. This filter was chosen to standardise clinical practice as it was suitable for all the monoclonal antibody infusions. The need to standardise this practice and maintain safety is discussed.<\/jats:p>","DOI":"10.12968\/bjon.2025.0567","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:02:41Z","timestamp":1769187761000},"source":"Crossref","is-referenced-by-count":1,"title":["The role of Pall Medical in-line filters in intravenous therapy administration: a comprehensive clinical perspective"],"prefix":"10.12968","volume":"35","author":[{"given":"Andrew","family":"Barton","sequence":"first","affiliation":[{"name":"Nurse Consultant, IV Therapy and Vascular Access, Frimley Health NHS Foundation Trust"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Melville","sequence":"additional","affiliation":[{"name":"Nurse Consultant and Lead for Vascular Access Services, Alder Hey Children's NHS Foundation Trust, Liverpool"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5130","reference":[{"key":"e_1_3_2_1_1","doi-asserted-by":"publisher","DOI":"10.1002\/ncp.11201"},{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2020.01.001"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2021.30.1.8"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpaic.2024.04.003"},{"key":"e_1_3_2_5_1","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in-vivo clinical use. EMA\/CHMP\/BMWP\/86289\/2010. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-monoclonal-antibodies-intended-vivo-clinical-use_en.pdf (accessed 17 December 2025)"},{"key":"e_1_3_2_6_1","unstructured":"European Medicines Agency. Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle. EMA\/CHMP\/CVMP\/83833\/2023. 2024. https:\/\/www.ema.europa.eu\/system\/files\/documents\/scientific-guideline\/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle-en.pdf (accessed 17 December 2025)"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000464"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033367"},{"key":"e_1_3_2_9_1","unstructured":"Hanifah S Ball PA Kennedy RA. Nature of precipitation resulted from intravenous drugs incompatibility. ASEAN Journal for Science and Engineering in Materials 2025;4(2):151\u2013158. https:\/\/ejournal.bumipublikasinusantara.id\/index.php\/ajsem\/article\/view\/623"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2539-7"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1051\/ject\/202052118"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001092"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crtox.2024.100175"},{"key":"e_1_3_2_14_1","unstructured":"Mistry P Hill A Puzovic M; Executive Committee & Faculty of the British Pharmaceutical Nutrition Group. Position statement: Use of filters during the administration of parenteral nutrition. Version 2. August 2025. https:\/\/www.bpng.co.uk\/file.php?f=ZWxlbWVudCMjMTQ3IyNmaWxlbmFtZQ== (accessed 17 December 2025)"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2023.32.Sup7.S4"},{"key":"e_1_3_2_16_1","unstructured":"National Institute for Health and Care Excellence. Neonatal parenteral nutrition. NICE Guideline NG154. 2020. https:\/\/www.nice.org.uk\/guidance\/ng154 (accessed 17 December 2025)"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03112-1"},{"key":"e_1_3_2_18_1","unstructured":"NHS England. Approved costing guidance. 2025. https:\/\/www.england.nhs.uk\/long-read\/approved-costing-guidance-2025-introduction\/ (accessed 6 January 2026"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000532"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2213296"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8112017"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2618-z"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000905]"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1129729821989165"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000003393"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ncp.10587"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-2508-2733"}],"container-title":["British Journal of Nursing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/pdf\/10.12968\/bjon.2025.0567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:02:42Z","timestamp":1769187762000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/10.12968\/bjon.2025.0567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,22]]}},"alternative-id":["10.12968\/bjon.2025.0567"],"URL":"https:\/\/doi.org\/10.12968\/bjon.2025.0567","relation":{},"ISSN":["0966-0461","2052-2819"],"issn-type":[{"value":"0966-0461","type":"print"},{"value":"2052-2819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}